Prenatal Exposure to Emerging Contaminants and Children's Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Other: Gestational Exposure to Emerging Contaminants (ECs)
- Registration Number
- NCT06316609
- Lead Sponsor
- Children's Hospital of Fudan University
- Brief Summary
This prospective cohort study aims to investigate the association between prenatal blood levels of Emerging Contaminants and the five-year incidence of atopic dermatitis (AD) in offspring.
- Detailed Description
This prospective birth cohort study, conducted within the Shanghai prenatal population, involves the collection of maternal blood samples during gestation to directly measure the biological exposure levels of Emerging Contaminants, including Per- and Polyfluoroalkyl Substances (PFAS), Organophosphate Flame Retardants (OPFRs), and Microplastics. Serum and whole blood levels of these contaminants are evaluated during pregnancy at 12-14, 22-26, and 31-34 gestational weeks. Subsequently, the study assesses skin barrier function in infants at 24-48 hours, 42 days, and 6 months of age. During a five-year period, the occurrence of atopic dermatitis (AD) in offspring is assessed. The objectives of this cohort study are twofold: (1) to elucidate the relationship between maternal exposure to Emerging Contaminants and the development of AD in offspring, and (2) to evaluate the impact of such exposure on the skin barrier function of infants. This research aims to provide substantial evidence for the prevention of AD, offering a unique and meaningful approach to mitigating the incidence of AD.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 456
- Mother plans to proceed prenatal care and delivery in Minhang Maternal and Children Health Care Hospital
- 12-14 weeks of singleton pregnancy, non-stillborn or miscarrying, offspring without familial hereditary skin diseases
- Offspring plans to stay in Shanghai until 5 years and proceed follow-up at the Dermatology Department of Children's Hospital affiliated with Fudan University
- signed informed consent.
- Multiple pregnancies
- perinatal death
- a fetus with congenital skin or appendages disorders
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description participants from birth cohort without AD Gestational Exposure to Emerging Contaminants (ECs) The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the reduced incidence of atopic dermatitis in their offspring. participants from birth cohort with AD Gestational Exposure to Emerging Contaminants (ECs) The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the incidence of atopic dermatitis in their offspring.
- Primary Outcome Measures
Name Time Method atopic dermatitis: Infant atopic dermatitis incidence at 1 year old Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms.
- Secondary Outcome Measures
Name Time Method Umbilical cord serum Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at delivery. Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at second trimester 22-26 gestational weeks Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
prenatal exposure to Microplastics at mid pregnancy 22-26 gestational weeks Maternal whole blood levels of Microplastics
Allergic rhinitis incidence of allergic rhinitis at the age of five. An inquiry into the patient's medical history and electronic medical record
atopic dermatitis incidence of AD at the age of five. Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms.
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at early pregnancy 12-14 gestational weeks Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at second trimester 22-26 gestational weeks Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at late pregnancy 34-36 gestational weeks Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Infant skin barrier function (skin surface pH) infant 6 months old Skin pH will be evaluated by the device of Multi Probe Adapter 4.
prenatal exposure to Microplastics at late pregnancy 34-36 gestational weeks Maternal whole blood levels of Microplastics
Infantile hemangioma incidence of Infantile hemangioma at 1 year old Diagnosed by dermatologists
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at third trimester 34-36 gestational weeks Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at early pregnancy 12-14 gestational weeks Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at third trimester 34-36 gestational weeks Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
prenatal exposure to Microplastics at second trimester 22-26 gestational weeks Maternal serum levels of Microplastics
Umbilical cord serum Microplastics at delivery. Umbilical cord serum levels of Microplastics
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at mid pregnancy 22-26 gestational weeks Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at first trimester 12-14 gestational weeks Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Infant skin barrier function (Transepidermal Water Loss, TEWL） infant 6 months old TEWL will be evaluated by the device of Multi Probe Adapter 4.
Microplastics in Umbilical cord whole blood at delivery. Umbilical cord whole blood levels of Microplastics
Asthma incidence of asthma at the age of five. An inquiry into the patient's medical history and electronic medical record
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at late pregnancy 34-36 gestational weeks Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at first trimester 12-14 gestational weeks Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) in Umbilical cord whole blood at delivery Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
prenatal exposure to Organophosphate Flame Retardants (OPFRs) at mid pregnancy 22-26 gestational weeks Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP
Organophosphate Flame Retardants (OPFRs) in Umbilical cord whole blood at delivery Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Umbilical cord serum Organophosphate Flame Retardants (OPFRs) at delivery Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS
Infant skin barrier function (Stratum corneum hydration, SCH) infant 6 months old SCH will be evaluated by the device of Multi Probe Adapter 4.
Infant skin barrier function (sebum content) infant 6 months old Sebum content will be evaluated by the device of Multi Probe Adapter 4.
prenatal exposure to Microplastics at early pregnancy 12-14 gestational weeks Maternal whole blood levels of Microplastics
prenatal exposure to Microplastics at first trimester 12-14 gestational weeks Maternal serum levels of Microplastics
prenatal exposure to Microplastics at third trimester 34-36 gestational weeks Maternal serum levels of Microplastics
Trial Locations
- Locations (1)
Children Hospital of Fudan University
🇨🇳Shanghai, Shanghai, China